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Abstract
NMDA glutamate receptors play key roles in brain development, function, and dysfunction. 
Regulatory roles of D-serine in NMDA receptor-mediated synaptic plasticity have been reported. 
Nonetheless, it is unclear whether and how neonatal deficits in NMDA-receptor-mediated 
neurotransmission affect adult brain functions and behavior. Likewise, the role of D-serine during 
development remains elusive. Here we report behavioral and electrophysiological deficits 
associated with the frontal cortex in Pick1 knockout mice, which show D-serine deficits in a 
neonatal and forebrain specific manner. The pathological manifestations observed in adult Pick1 
mice are rescued by transient neonatal supplementation of D-serine, but not by a similar treatment 
in adulthood. These results indicate a role for D-serine in neurodevelopment and provide novel 
insights on how we interpret data of psychiatric genetics, indicating the involvement of genes 
associated with D-serine synthesis and degradation, as well as how we consider animal models 
with neonatal application of NMDA receptor antagonists.
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Introduction
NMDA glutamate receptors mediate excitatory neurotransmission and synaptic plasticity, 
and their modulation by endogenous factors has a critical role in these phenomena. 
Specifically, NMDA receptors are required for long-term potentiation (LTP) and long-term 
depression (LTD), cellular processes of neural plasticity that underlie learning and 
memory.1,2 NMDA receptors are activated by glutamate and require several co-agonists, 
including D-serine.3 A crucial role of D-serine in neural plasticity has also been 
demonstrated.4–6 On the other hand, excess NMDA receptor mediated signaling can lead to 
excitotoxicity, which may underlie many brain disorders, including stroke, Alzheimer’s 
disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).7–10 D-serine is also 
known to play a role in this toxic cascade in a context-dependent manner, including in some 
cases of stroke and ALS.11–13
During brain development, NMDA receptors are crucial for the generation of spontaneous 
synchronous network activity in the neonatal brain.14–17 NMDA receptors are also essential 
for the conversion of silent to active synapses by recruiting AMPA receptors.18 However, it 
is unclear whether and how neonatal deficits in NMDA-receptor-mediated 
neurotransmission affect adult brain functions and behavior. Likewise, the role of D-serine 
during development remains elusive. Given that NMDA receptors are modulated by D-
serine, animal models with transient deficits in D-serine during neonatal stages may provide 
a good tool to address this question.
PICK1 is a multifunctional scaffold protein that interacts with many proteins, including 
several types of glutamate receptors and serine racemase, the D-serine synthesizing 
enzyme.19,20 PICK1 has been extensively studied in the context of neural plasticity,21–32 and 
mice deficient in Pick1 are also available.22 Nonetheless, the physiological role of PICK1-
serine racemase protein interactions remains elusive. In cell cultures, PICK1 can augment 
the enzymatic activity of serine racemase and D-serine synthesis.21 Pick1 knockout mice 
display a significant reduction in D-serine levels, which is specific to the forebrain during 
the neonatal stage: the level of D-serine is normal in adult Pick1 mice.21
Here we aimed to address the significance of D-serine in brain development on adult brain 
function and behavior, by using Pick1 knockout mice. As the first step, we examined 
behavioral and electrophysiological characteristics associated with the frontal cortex of the 
Pick1 mice. We then tested whether the representative deficits in adulthood are normalized 
by transiently supplying D-serine only during the neonatal stage.
Nomura et al. Page 2
Mol Psychiatry. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Materials and Methods
Animals
We used C57BL/6J male Pick1 knockout mice,21 which have been previously characterized 
in the context of hippocampal and cerebellar neural plasticity.23,33 For all groups, pups were 
weaned on postnatal day 21, genotyped and housed in sex-matched groups of five in 
standard mouse cages in accordance with protocols approved by the Johns Hopkins 
University, the University of Maryland, and RIKEN Animal Care and Use Committees.
Behavioral Tests
Behavioral tests were conducted on male Pick1 knockout mice and control littermates in 
adulthood (over 2 months of age), with a one-week interval between tests. We conducted the 
assays based on our published protocols with minor modifications.34–40
Open field test—Horizontal and vertical locomotor activity were assessed for 2 h using 
activity chambers equipped with infrared beams (San Diego Instruments). Horizontal and 
vertical movements, stereotypies, and time spent in the center or along the walls of the 
chamber (thigmotaxis) were automatically recorded.
Prepulse inhibition (PPI) of the acoustic startle—The PPI test was performed as 
previously described.35,40 Two identical startle chambers (San Diego Instruments) were used 
for measuring startle reactivity. During each PPI session, a mouse was exposed to the 
following types of trials: pulse alone (a 120 dB, 100 ms, broadband burst); the omission of 
stimuli (no-stimulus trial); and four prepulse–pulse combinations (prepulse–pulse trials) 
consisting of a 20 ms broadband burst used as a prepulse and presented 80 ms before the 
pulse using one of five prepulse intensities (74, 78, 82, 86, and 90 dB). Each session 
consisted of six presentations of each type of trial presented in a pseudorandom order. The 
background noise presented throughout the entire session was 70 dB.
Forced Swim Test (FST)—The FST was employed to evaluate depression-associated 
responses. Latency to immobility and total immobility were analyzed during the last 4 min 
of the 6 min test using the SMART program (San Diego Instruments).
Elevated plus maze (EPM)—The EPM was used to assess anxiety as described 
previously.35 Anxiety was measured by the percent of time spent in the open arms 
[calculated as 100× (time spent in the open arms/(time in the open arms + time in the closed 
arms)].
Y-maze—Spontaneous alternation as a measure of spatial working memory was assessed in 
the Y-maze. The spontaneous alternation behavior was calculated as the number of triads 
(visiting three different arms on consecutive choices, e.g., ABC, but not ABB or ACC) 
divided by the total number of arms entered minus two.41
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Quantitative real time PCR
Quantitative real-time PCR was performed by the ABI Prism 7900HT sequence detection 
system (Applied Biosystems). Note, we performed this molecular study with frontal cortex 
homogenates from mice that had been injected with saline for another assay. The primers 
used for the study were as follows:
Stargazin (forward): 5’-ccagcaagaagaacgaggaa-3’
Stargazin (reverse): 5’-ttgcttgcacagacctttga-3’
Parvalbumin (forward): 5’-ttctggacaaagacaaaagtgg-3’
Parvalbumin (reverse): 5’-tgaggagaagcccttcagaat-3’
Gad67 (forward): 5’-tggagcagatcctggttgact-3’
Gad67 (reverse): 5’-gccattcaccagctaaaccaa-3’
Actin (forward): 5’-gatgacgatatcgctgcgctggtcg-3’
Actin (reverse): 5’-gcctgtggtacgaccagaggcatacag-3’
Electrophysiology
Adult mice were anesthetized with chloral hydrate (400 mg/kg i.p.) and perfused with ice 
cold artificial cerebrospinal fluid (ACSF, in mM: 125 NaCl, 25 NaHCO3, 10 glucose, 3.5 
KCl, 1.25 NaH2PO4, 0.5 CaCl2, 3 MgCl2, 0.075 Na2S2O5, pH 7.4). Coronal brain slices 
(300 µm) containing the medial prefrontal cortex were made with a Vibratome and incubated 
for at least 1 h at 35°C. Recordings were made using 35°C O2-saturated ACSF, but with 
CaCl2 adjusted to 2 mM and MgCl2 to 1 mM. Recording electrodes were made from glass 
pipettes filled with (in mM) 115 K-gluconate, 10 HEPES, 2 MgCl2, 20 KCl, 2 Mg-ATP, 2 
Na2-ATP, 0.3 GTP (pH 7.3; 280 mOsm) and Neurobiotin (0.125%). Prefrontal cortical 
pyramidal neurons were identified under visual guidance using infrared-differential 
interference contrast (IR-DIC) video microscopy (Olympus BX50-WI). Whole-cell current-
clamp signals were amplified (10x) with a Multiclamp 700B (Axon Instruments), digitized 
with an A/D converter (Digidata, Axon Instruments) and sampled with Axoscope 9.0 (Axon 
Instruments) at 20 KHz.42
Neonatal or adult D-serine treatment (Fig. 3)
D-serine (500 mg/kg; Sigma-Aldrich) was dissolved in sterile physiological saline and 
administered intraperitoneally (i.p.), using a 30-gauge needle, every day for 2 weeks 
beginning on postnatal day 3 (P3). The dose was chosen according to a representative 
publication, which showed that 300–900 mg/kg of D-serine ameliorated a PPI deficit 
induced by dizocilpine in adult mice.43 The effects of D-serine were evaluated in adulthood 
using the PPI and Y-maze tests and electrophysiological recordings assessing NMDA 
modulation of pyramidal cell firing in prefrontal cortical slices.
Since it was a control experiment, the conditions of the adult D-serine treatment were the 
same as the neonatal treatment (500 mg/kg i.p daily for 2 weeks) except for the timing: it 
started at the age of 8 weeks. After two weeks of treatment we waited one week to avoid 
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acute effects of the D-serine and then did either electrophysiology or behavioral testing (Y-
maze followed by PPI after another one week interval).
Statistical Analysis
Statistical analysis was performed by ANOVA. A student’s t-test was used to compare two 
sets of data. Values in graphs are expressed as the mean plus the standard error of the mean 
(SEM). Significance levels are marked as follows: *P < 0.05.
Results
Behavioral and molecular alterations in adult Pick1 knockout mice
We analyzed the behavioral consequences of deleting the Pick1 gene by performing 
behavioral tests relevant to diverse aspects of mental conditions. Pick1 knockout mice did 
not differ from wild-type littermates in open field activity over 2 h (Supplementary Fig. 1), 
but when we divided the 2 h into four bins of 30 min, we found them to be significantly 
hyperactive during the 60–90 min interval (Fig. 1A, Supplementary Fig. 1). The 
hyperactivity of Pick1 knockout mice was unlikely related to altered emotionality, as no 
significant group differences were seen in the elevated plus maze and the forced swim test 
(Fig. 1B, C, Supplementary Fig. 2). We also assessed prepulse inhibition (PPI) of the 
acoustic startle response, a measure of sensorimotor gating, which is reportedly impaired in 
patients with several neuropsychiatric disorders, including schizophrenia (Fig. 1D).44 Two-
way repeated measures ANOVA showed a significant group effect, F(1,89)=6.04, p=0.026 
and significant group by prepulse interaction, F(4,89)=6.21, p<0.001. Post-hoc tests 
demonstrated that, compared to controls, knockouts had significantly decreased PPI at the 
prepulse intensities of 74, 78 and 82 dB. Notably, Pick1 knockout mice showed an increase 
in startle response, indicating that impaired PPI was not due to insufficient startle response 
(Supplementary Fig. 3). In addition, Pick1 knockout mice also exhibited significantly fewer 
spontaneous alternations in the Y-maze compared to wild-type mice (Fig. 1E), which is a 
sign of working memory deficit.44,45 Abnormalities in PPI and working memory could 
result from deficits of the prefrontal cortex.46 We also conducted an exploratory expression 
study for candidate molecules (AMPA receptor regulator Stargazin and interneuron markers 
of Parvalbumin and Gad67): real-time PCR indicated an increase in the expression of 
Stargazin and Parvalbumin, but not that of Gad67, in adult Pick1 knockout mice 
(Supplementary Fig. 4).
Alterations in NMDA-elicited firing of prefrontal cortical pyramidal neurons in adult Pick1 
knockout mice
As behavioral deficits in Pick1 mice suggested altered prefrontal cortical function, we 
hypothesized that pyramidal neurons in the prefrontal cortex of Pick1 knockout mice may 
display altered physiological properties. To address this question, we tested the excitability 
of pyramidal neurons in brain slices containing the prefrontal cortex of adult Pick1 knockout 
mice and wild-type littermates. The number of action potentials evoked with intracellular 
current injections before and after bath application of NMDA (4 µM) was examined as a 
readout of cell excitability (Fig. 2, Supplementary Table 1). We also tested whether the 
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modulation of NMDA responses by D1 dopamine receptors is affected in Pick1 knockout 
mice by adding the selective D1 agonist SKF38393 (2 µM).42
The resting membrane potential was not different between wild-type and Pick1 knockout 
mice, and was not affected by the addition of NMDA and SKF38393 (wild-type: −63.3 ± 1.5 
mV at baseline, −62.0 ± 2.2 mV with NMDA, −60.3 ± 3.6 mV with NMDA and SKF38393; 
Pick1 knockout mice: −65.8 ± 3.1 mV at baseline, −63.5 ± 3.1 mV with NMDA, −62.0 ± 5.7 
mV with NMDA and SKF38393). Thus, basic membrane properties of prefrontal pyramidal 
neurons were not affected in Pick1 knockout mice.
We then tested whether Pick1 knockout mice exhibited altered modulation of excitability by 
NMDA in pyramidal neurons. The number of action potentials evoked by a constant-
amplitude current pulse was markedly increased by application of NMDA in wild-type mice 
(from 6.6 ± 0.5 to 11.4 ± 2.8 spikes; a 73% increase from baseline) (Fig. 2, Supplementary 
Table 1). Although the D1 agonist SKF38393 alone did not change the number of action 
potentials, the combined addition of NMDA and SKF38393 synergistically augmented the 
number of action potentials (to 13.1 ± 4.8; a 101% increase from baseline) in wild-type 
mice. In Pick1 knockout mice, however, the increase in the number of action potentials by 
NMDA was significantly attenuated (from 5.8 ± 1.7 to 7.8 ± 2.3; a 33% increase from 
baseline), and the addition of SKF38393 to NMDA only slightly elevated the response (to 
8.5 ± 3.4; a 45% increase from baseline). A two-way ANOVA with genotype and drug 
treatment as factors revealed genotype differences (ANOVA F1,22=5.82, p=0.024), indicating 
that NMDA responses are impaired in Pick1 knockout mice. There was no significant 
interaction between genotype and D1 agonist treatment (p=0.914), indicating that D1 
modulation of NMDA responses was not affected in Pick1 knockout mice.
Influence of neonatal D-serine on behavioral defects in adult Pick1 knockout mice
Here we show that Pick1 knockout mice have prefrontal cortex-associated behavioral 
deficits in adulthood. Which mechanism(s) underlie these deficits? One possibility is that 
down-regulation of D-serine during development, at the neonatal stage, may contribute to 
these adult deficits in Pick1 knockout mice. To address this question, we administered D-
serine (500 mg/kg, i.p.) daily to pups beginning on postnatal day 3 (P3) for 2 weeks, and 
then maintained the animals until adulthood without any further supplementation of D-serine 
(Fig. 3). We did not observe any adverse effects of neonatal injections (data not shown). We 
evaluated the effects of this neonatal treatment with D-serine by monitoring possible 
improvement in PPI and spontaneous alternations in the Y-maze in adult mice. Compared to 
saline treatment, D-serine treatment in the neonatal stage significantly increased the PPI in 
Pick1 knockout, but not in wild-type mice (Fig. 4). We assessed the PPI effects separately 
for Pick1 knockout mice and wild-type mice, as our pilot data had not revealed effects of D-
serine on wild-types; this design increases the power of analysis. Two-way repeated 
measures ANOVA of the data for knockout mice revealed a significant effect of treatment, 
F(1,99)=4.8, p=0.041, but not for wild-type mice, F(1,64)=0.6, p=0.47. A trend of beneficial 
effect of neonatal D-serine treatment was also seen in the adult behaviors in Y-maze 
(Supplementary Fig. 5). Note, due to unexpected baseline changes elicited by neonatal 
injection itself, this statement on Y-maze is not conclusive.
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We also tested the impact of adult D-serine administration (500 mg/kg, i.p.; daily beginning 
at the age of 8 weeks for 2 weeks) on these behaviors. In regard to PPI, we cannot make any 
meaningful statements because repeated injections in adulthood significantly altered the 
baseline response in both wild-type and knockout mice (Supplementary Fig. 6A). 
Meanwhile, we observed conclusive evidence that adult D-serine treatment did not rescue 
the deficit in spontaneous alternations in Pick1 knockout mice (Supplementary Fig. 6B).
Influence of neonatal D-serine on electrophysiological defects in adult Pick1 knockout 
mice
We next addressed whether neonatal D-serine treatment of Pick1 knockout mice may 
normalize the electrophysiological deficits observed in adult mice. We prepared prefrontal 
cortical slices from D-serine-treated Pick1 knockout mice, and conducted 
electrophysiological assessments similar to those presented in Fig. 2. The resting membrane 
potentials of Pick1 knockout mice treated with D-serine during the neonatal period and 
adulthood were −66.6 ± 4.7 and −67.9 ± 3.1 mV, respectively. Unlike untreated Pick1 
knockout mice, NMDA (4 µM) elicited strong increases in evoked action potential firing in 
slices from D-serine-treated Pick1 knockout mice. The number of action potentials evoked 
by current injection rose from 3.9 ± 1.2 to 7.4 ± 3.2 with NMDA administration (89% 
increase from baseline) (Fig. 5A, Supplementary Table 1). The addition of SKF38393 to 
NMDA slightly increased the number of action potentials to 8.9 ± 3.6. A two-way ANOVA 
revealed differences between treated and untreated Pick1 knockout mice (F1,22=7.91, 
p=0.010). These results indicate that D-serine treatment during development rescued adult 
NMDA function in Pick1 knockout mice.
In contrast, when we conducted D-serine treatment in adulthood, responses of neurons were 
noticeably blunted in Pick1 knockout mice: to NMDA (5.7 ± 1.7 at baseline to 8.2 ± 3.2 
spikes for a 46% increase in action potential firing) or NMDA plus SKF38393 (9.7 ± 3.6, a 
70% increase from baseline) (Fig. 5B, Supplementary Table 1). To statistically confirm the 
contrastive responses between neonatal and adult D-serine treatment to Pick1 mice, we 
employed a two-way ANOVA. First, a significant effect of D-serine treatment (F2,42=7.502, 
p=0.002) was revealed in Pick1 mice. Second, post hoc comparisons using Tukey’s HSD 
indicate that neonatal treatment rescued the electrophysiological deficits in untreated Pick1 
mice (p=0.002), whereas this rescue was absent upon the treatment in adulthood (p=0.52). 
Thus, we conclude that neonatal, but not adult, D-serine treatment rescues NMDA function 
in adult Pick1 knockout mice.
Discussion
It has been an unanswered question whether D-serine during brain development plays a role 
in adult brain function and behavior, although its physiological and pathological role in adult 
animals have been well studied.6,43,47–50 To address this question, here we utilized Pick1 
knockout mice in which the D-serine level is selectively reduced in the forebrain only during 
the neonatal stage.21 Adult Pick1 knockout mice showed several behavioral abnormalities 
and electrophysiological deficits in the prefrontal cortex. Importantly, neonatal, but not 
adult, D-serine supplement rescued such adult deficits. These observations suggest a novel 
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role for D-serine during brain development, with significant influence on adult brain 
function and behavior.
How does altered D-serine during development affect adult performance? The most probable 
scenario is that neonatal D-serine influences NMDA receptors, which in turn affects brain 
network formation. In Pick1 knockout mice, a neonatal-specific deficit in D-serine may lead 
to transient hypo-NMDA function during a critical period for proper brain development. 
Alternatively, D-serine may influence brain development by an unknown mechanism 
independent of its action on NMDA receptors. The next question, although it is beyond the 
scope of the present study, is to characterize how neonatal D-serine administration to Pick1 
knockout mice may change (possibly normalize) neural network formation during the 
developmental trajectory, in comparison with non-treated Pick1 knockout and wild-type 
mice. By comparing these data with those from mice with direct genetic modulation of 
NMDA receptors, we may be able to clarify whether the effects of neonatal D-serine supply 
are via NMDA receptors.
Acute or sub-chronic administration of phencyclidine (PCP), a NMDA receptor antagonist, 
to rodents can produce behaviors resembling phenomena observed in schizophrenia.51 
Clinical observation of PCP-induced psychosis and schizophrenia-like manifestation in 
normal subjects with non-competing NMDA receptor antagonists indicate a possible role of 
adult NMDA neurotransmission in the disease.52,53,54 The current view on the mechanisms 
by which NMDA antagonists may produce psychosis relates to their ability to selectively 
suppress local inhibitory processes yielding cortical disinhibition and these effects are 
evident in adolescents and adults.55 Thus, the mechanism leading to behavioral deficits in 
Pick1 knockout mice is different from those elicited by adult and adolescent administration 
of NMDA receptor antagonists that functionally impair glutamatergic neurotransmission.56 
Instead, as discussed above, neonatal D-serine and NMDA receptors are likely to influence 
neural circuit formation during neurodevelopment, secondarily affecting adult brain function 
and behavior in neonatal manipulations that reduce NMDA receptor activity. Thus, neonatal 
administration of PCP may be a useful model for adult mental illnesses,57–60 but is justified 
in the context of neurodevelopment, distinct from models with adult and adolescent 
administration of NMDA receptor antagonists.
As PICK1 is a multifunctional protein, the phenotypes of Pick1 knockout mice reflect not 
only D-serine associated abnormalities but also deficits elicited by many other mechanisms. 
Thus, in the present study, we conducted neonatal supplement of D-serine to address the 
primary cause of D-serine. Nonetheless, one may wonder why we did not use conditional 
knockout mice lacking serine racemase,61 the synthesizing enzyme for D-serine, for this 
study. This is in part because we currently do not have access to the conditional mice. 
Furthermore, as Serine racemase generates not only D-serine but also pyruvate, keto-acid, 
and ammonia,62 its knockout may not be a tool to purely address the role for D-serine. Thus, 
both conditional serine racemase knockout and Pick1 knockout mice are complementary 
towards investigating the neonatal role for D-serine.
Genetic studies have suggested that genes encoding key molecules of D-serine synthesis, 
degradation, and regulation (e.g., D-amino acid oxidase, serine racemase, and possibly G72) 
Nomura et al. Page 8
Mol Psychiatry. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
are frequently associated with bipolar disorder and schizophrenia.63–65 A recent genome 
wide association study has indicated 108 chromosomal loci that associate with 
schizophrenia, which include the locus of the serine racemase gene.66 In addition, a 
chromosomal abnormality associated with schizophrenia is reportedly linked to down-
regulation of phosphoserine aminotransferase1, PSAT1, a key enzyme for the synthesis of L-
serine, the precursor of D-serine.70 Some studies have found reduced D-serine in the 
cerebrospinal fluid of patients with schizohprenia,67,68 whereas, other studies including a 
meta-analysis found no differences.69 Accordingly, the Pick1 knockout mice with D-serine 
deficit specific to neonatal stage may model schizophrenia in which adult D-serine level is 
normal.
Thus far, NMDA hypofunction has been modeled primarily using experimental animals, 
which include the serine racemase knockout mice in which D-serine deficiencies are present 
throughout life. The Pick1 knockout model offers a unique opportunity to investigate the 
role of D-serine deficiency limited to the neonatal stage for behavior during adulthood. Our 
findings demonstrate that neonatal D-serine deficiency, on its own, is sufficient to induce 
some behavioral phenotypes, such as impaired prepulse inhibition and spontaneous 
alternation that may serve as pathophysiological markers for schizophrenia or other major 
mental disorders, and that such effects are rescued by neonatal D-serine treatment. Future 
studies are needed to determine the relative importance of neonatal vs. adult D-serine 
deficiency in the pathology of major mental illness.
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Figure 1. Behavioral changes in adult male Pick1 knockout mice in adulthood
A) Horizontal locomotor activity. There was a significant group by interval interaction 
[F(23, 383)=1.83, p=0.012]. Pairwise multiple comparison procedures (Holm-Sidak method) 
showed significantly more ambulatory activity in Pick1 knockout mice at the 60–90 min 
interval (*p<0.05), p=0.054 for the 90–120 interval, n=8 per group.
B) Behavior in the elevated plus maze. No difference between wild-type and Pick1 knockout 
and mice was observed. n=7 per group.
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C) Time immobile in the forced swim test. No differences between wild-type and Pick1 
knockout mice was observed. n=8 per group.
D) Prepulse inhibition (PPI) of the acoustic startle. Pick1 knockout mice demonstrated 
significantly lower PPI at the prepulse intensities of 74, 78 and 82 dB. *p<0.05 vs. wild-type 
at the same prepulse intensity. n=11 (knockout), n=8 (wild-type).
E) Spontaneous alternations in the Y maze. Pick1 knockout mice showed significantly fewer 
alternations in the Y maze compared to wild-type mice, *p<0.05, n=8 per group.
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Figure 2. NMDA effects on prefrontal cortex pyramidal cell excitability in adult Pick1 knockout 
mice
Top: Examples of traces used to assess excitability 5 min before 4 µM NMDA application 
(left), after 5 min of NMDA perfusion, after 5 min of the D1 agonist SKF38393 (SKF, 2 
µM), and during the combined perfusion of 4 µM NMDA and 2 µM SKF in a prefrontal 
cortical slice from a wild-type mouse. The rectangular area with the red line indicates the 
changes in the number of evoked action potentials over time with the three treatments 
(NMDA alone, SKF alone, NMDA+SKF, shaded areas). The vertical arrows indicate the 
time at which the traces on top were obtained. Right, population data indicating normalized 
responses to baseline after NMDA alone and NMDA + SKF. Bottom: Similar display for a 
representative prefrontal cortex prefrontal cortex pyramidal neuron in a Pick1 knockout 
mouse (left) and population data for NMDA and NMDA + SKF for all knockout mice 
recorded, showing a reduced NMDA effect in slices from Pick1 knockout mice.
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Figure 3. Time line for D-serine treatment and summary of results
We have previously published that Pick1 knockout mice have reduced D-serine levels at P7 
(neonatal stage), but not in adulthood (P56) (Hikida 2008). Based on those results, here we 
tested whether supplementation of D-serine during the neonatal period (P3–P17) would 
improve behavioral and electrophysiological deficits seen in adulthood and indeed it did. As 
a control experiment we also treated the mice with D-serine in adulthood (P56–P70), 
followed by a washout period of 1 week, and found no effect on behavior or 
electrophysiology.
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Figure 4. Effect of neonatal D-serine treatment on PPI in adulthood
D-serine 500 (mg/kg) was injected daily for 2 weeks starting on postnatal day 3. The PPI 
deficit was significantly rescued in adult Pick1 knockout mice treated with D-serine in the 
neonatal stage. Two-way repeated measures ANOVA of the data for knockout mice revealed 
a significant effect of treatment, F(1,99)=4.8, p=0.041. n=8, wild-type with saline treatment; 
n=8, wild-type with D-serine treatment; n=5, Pick1 knockout mice with saline treatment; 
n=13, Pick1 knockout mice with D-serine treatment.
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Figure 5. Rescue of electrophysiological deficits in adulthood by neonatal D-serine treatment, but 
not by adult D-serine treatment
Responses to NMDA application in prefrontal cortical brain slices from adult Pick1 
knockout mice that had been treated with D-serine. Data are presented in the same format of 
those in Fig. 2.
A) Neonatal D-serine treatment (from postnatal day 3 to day 16) rescued the 
electrophysiological changes in Pick1 knockout mice.
B) Adult D-serine treatment did not rescue the electrophysiological changes in Pick1 
knockout mice.
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